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Abstract
Background: Whole exome sequencing provides a labor-saving and direct means of genetic diagnosis of hereditary
disorders in which the pathogenic gene harbors a large cohort of exons. We set out to demonstrate a suitable example of
genetic diagnosis of MEN 2A/FMTC (multiple endocrine neoplasia type 2/familial medullary thyroid carcinoma) using this
approach.
Methodology/Principal Findings: We sequenced the whole exome of six individuals from a large Chinese MEN2A/FMTC
pedigree to identify the variants of the RET (REarranged during Transfection) protooncogene and followed this by
validation. Then prophylactic or surgical thyroidectomy with modified or level VI lymph node dissection and adrenalectomy
were performed for the carriers. The cases were closely followed up. Massively parallel sequencing revealed four missense
mutations of RET. We unexpectedly discovered that the proband’s daughter with MEN 2A-related MTC presented a novel
p.C634Y/V292M/R67H/R982C compound mutation, due to the involvement of p.C634Y in the proband with MEN 2A and
p.V292M/R67H/R982C in the proband’s husband with FMTC. In the maternal origin, p.C634Y caused bilateral MTC in all 5
cases and bilateral pheochromocytoma in 2 of the 5; the earliest onset age was 28 years. In the paternal origin, one of the six
p.V292M/R67H/R982C carriers presented bilateral MTC (70 years old), one only had bilateral C-cell hyperplasia (44 years),
two had bilateral multi-nodules (46 and 48 years) and two showed no abnormality (22 and 19 years).
Conclusions/Significance: The results confirmed the successful clinical utility of whole exome sequencing, and our data
suggested that the p.C634Y/V292M/R67H/R982C mutation of RET exhibited a more aggressive clinical phenotype than
p.C634Y or p.V292M/R67H/R982C, while p.V292M/R67H/R982C presented a relatively milder pathogenicity of MTC and likely
predisposed to FMTC.
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Introduction
The REarranged during Transfection (RET) protooncogene
containing 21 exons is mapped on chromosome 10q11.2 and encodes
a tyrosine kinase receptor that plays a crucial role in regulating cell
proliferation, migration, differentiation, and survival through embryo-
genesis [1,2]. Germline mutations of RET are found in multiple
endocrine neoplasia type 2 (MEN2) and Hirschsprung disease (HSCR)
in an autosomal dominant pattern [3,4]. MEN 2 is subtyped into MEN
2A, MEN 2B, and familial medullary thyroid carcinoma (FMTC)
based on the different tissues involved [5]. MEN 2A, the most common
clinical subtype, is characterized by the MTC triad in nearly 95%,
pheochromocytoma (PHEO) in 50–57%, and hyperparathyroidism
(HPT) in 15–30% of cases [5–7]. MEN 2B is similar to MEN 2A
except that HPT is rare, and characteristic developmental abnormal-
ities, such as marfanoid habitus and ganglioneuromatosis of the
intestinal tract, are present [5]. FMTC is defined by the sole presence
of MTC as the disease phenotype [5]. MEN 2 and HSCR are usually
distinct but occasional families have been reported with both diseases
[4]. In HSCR, RET mutations are dispersed throughout the gene with
poor genotype-phenotype correlation [4], while all the MEN 2
mutations target within exons 5, 8, 10, 11, and 13 to 16 with strong
genotype-phenotype correlations [5–7]. More than 95% of MEN2A
and FMTC patients have a RET mutation typically occurring at one of
the five cysteine residues (codons 609, 611, 618, and 620 within exon
10, and codon 634 within exon 11). Biochemical and biological
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dimerization of the RET protein, leading to constitutive activation of its
intrinsic tyrosine kinase activity [8]. Other mutations within exons 8,
10, 11, and 13 to 16 appear to account for a small percentage of
FMTC families [7,9]. MEN 2B is mainly associated with mutation of
codon 918 within exon 16 [5]. A second mutation at codon 883 within
exon 15 and tandem RET mutations of codons 805, 806, and 904 in cis
configuration with the p.V804M mutation have also been reported in
individuals with MEN 2B [4,8,10,11]. Recently, Castellone et al found
a p.V292M mutation within exon 5 in an Italian man with MTC and
PHEO and suggested that the mutant had low-grade transforming
potential [12]. Emerging reports of compound RET mutations appear
to show modulation of the degree of aggressiveness and the
development of unusual features of MTC [13]. p.R982C, a rare
polymorphism within exon 18 with a frequency of about 2%, was first
reported in HSCR [14]. p.R67H combined with p.R982C was
reported to be associated with congenital central hypoventilation
syndrome [15].
Protein-coding genes constitute only approximately 1% of the
human genome but harbor nearly 85% of the disease-causing
mutations at individual Mendelian loci [16–18]. Therefore, efficient
strategies for selectively sequencing complete coding regions can serve
as a genome-wide scan for the pathogenic gene [17–19]. Whole exome
capture and massively parallel DNA sequencing has provided a labor-
saving, reproducible and robust method for disease gene discovery and
clinical diagnosis [18,20]. Here, we used whole exome sequencing
(WES), coupling the Agilent whole exome capture system to the
Illumina HiSeq 2000 DNA sequencing platform, to identify a Chinese
female with MEN 2A-related MTC carrying the p.C634Y/V292M/
R67H/R982C mutation of RET, in whom p.C634Y was maternal
with 5 carriers with MEN2A, and p.V292M/R67H/R982C was
paternal with 6 carriers.
Methods
Subjects
A 22-year-old woman with MEN 2A-related MTC and
her brother, and 10 paternal and 12 maternal individuals from a
four-generation southern Chinese family (Fig. 1), and 100
unrelated healthy matched controls were studied.
This study was conducted in conformity with the Helsinki
Declaration and approved by the Ethics Committee of the 117
th
PLA Hospital. Written informed consent was given by all subjects.
Clinical Investigation
Clinical evaluation of MEN 2A/FMTC was performed
according to the published criteria [6,7,21]. The following
parameters were studied: clinical and diagnostic data (age, gender
and clinical features), biochemical markers (serum calcitonin (Ct),
carcinoembryonic antigen (CEA), parathyroid hormone, catechol-
amines), Doppler ultrasound (US) and computerized tomography
(CT) scans. Prophylactic or surgical thyroidectomy with neck
dissection and adrenalectomy was performed after confirmation of
RET mutations for the diagnosis. Then follow-up was carried out.
Exome Capture and Massively Parallel DNA Sequencing
The peripheral blood genomic DNA samples from each of six
family members (II-5, III-10, III-11, III-12, IV-10 and IV-11) were
randomly fragmented by Covaris to provide DNA fragments with
a base pair peak at 150 to 200 bp, then adapters were ligated to
both ends of the resulting fragments. The adapter-ligated
templates were purified by Agencourt AMPure SPRI beads, and
fragments with an insert size of ,200 bp were excised. Extracted
DNA was amplified by ligation-mediated PCR (LM-PCR),
purified, and hybridized to the SureSelect Biotinylated RNA
Library for enrichment; hybridized fragments were bound to
strepavidin beads whereas non-hybridized fragments were washed
out. Captured LM-PCR products were subjected to an Agilent
2100 Bioanalyzer to estimate the magnitude of enrichment. Each
captured library was then loaded onto the Hiseq2000 platform,
and we performed GA sequencing for each captured library
independently to ensure each sample had at least 50-fold coverage.
Raw image files were processed by Illumina Pipeline v1.6 for base-
calling with default parameters and the sequences of each
individual were generated as 90 bp paired-end reads.
SOAPaligner (soap2.21) was used to align the clean reads to the
human reference genome. Based on the SOAP alignment results,
the software SOAPsnp was used to assemble the consensus
sequence and call genotypes in target regions [22]. We filtered the
SOAPsnp results as follows: base quality more than 20, depth
between 4 and 200, estimate copy number equal to or less than 2
and the distance between two SNPs no less than 5. Detailed
information of each parameter for the two algorithms is available
at http://soap.genomics.org.cn/.
Data from the dbSNP129 and 1000 Genome Project (20100208
release) were downloaded from the NCBI FTP site (http://www.
ncbi.nlm.nih.gov/Ftp/). Target regions were from the captured
Figure 1. Pedigree of the family investigated (numbers indicate available).
doi:10.1371/journal.pone.0020353.g001
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downloads/annotation/seqcap_exome/index.html). The exome
variation set of eight HapMap samples was obtained from
‘‘Supplementary data 2’’ of 12 exomes in Ng et al [20].
RET Mutation Confirmation
To further confirmthe RETsubstitution mutations and the pattern
of the compound mutation in the proband’s daughter, we isolated
DNA and total RNA from peripheral blood and tumor tissues (MTC
from III-11 and III-20, PHEO from III-12) respectively, and
performed polymerase chain reaction (PCR) amplification of all
RET exons followed by Sanger sequencing, restriction endonuclease
digestion, reverse transcription PCR (RT-PCR)/sequencing, and
haplotype analysis of four RET-flanking microsatellite markers
(D10S197, D10S196, D10S1652 and D10S537).
All new data have been deposited in GenBank.
Results
Clinical Features and Phenotypic Data
The proband (III-12) was a 43-year-old woman who had been
diagnosed as having MTC in 1995 with a 4-year history of a
palpable neck mass in the right thyroid. Biochemical examination
disclosed increased CEA (17.7 ng/mL, normal ,5 ng/mL) and
Ct (408.32 ng/L, normal ,100 ng/L), while US scanning
disclosed multi-centric hypoechoic nodules with calcifications in
both thyroid lobes. Then a total bilateral thyroidectomy with
modified neck dissection was performed and histopathological
examination showed bilateral multi-centric MTC with lymph
node metastases (T2N1aM0, Table 1). Since surgery, she has been
receiving L-T4 substitution therapy. Her father died of thyroid
cancer in 1992. In 2001, the proband’s 13-year-old daughter (IV-
10) was diagnosed as having MTC with a 1-year history (first
diagnosed as multi-nodular goiter rather than MTC). Surveillance
found that the palpable neck mass in the left thyroid lobe increased
in size and reached a maximum diameter of 3.9 cm. Ct was
elevated to 343.92 ng/L and CEA was 14.7 ng/mL. US and CT
scanning disclosed multi-centric nodules with calcifications in both
lobes. Then, IV-10 received a total thyroidectomy with modified
bilateral neck dissection. Histopathology revealed multi-centric
MTC with lymph node metastases (T2N1aM0, Table 1). In 2005,
the proband’s 45-year-old male cousin (III-23) presented with
headache, paroxysmal hypertension, dizzy spells, and excess serum
catecholamine (Tables 1 and 2). US and CT scanning confirmed
bilateral masses in the adrenal glands. After treatment with a-
blockers, he underwent a total bilateral laparoscopic adrenalecto-
my with CO2 pneumoperitoneum; bilateral PHEO was confirmed
by histopathological examination. In 2006, the proband’s 52-year-
old female cousin (III-20) underwent a total thyroidectomy with
modified bilateral neck dissection based on the evidence of
elevated Ct and CEA and multi-centric nodules with calcifications
in both thyroid lobes but without adrenal abnormalities. In 2010,
some previously hesitant members of the family (III-13, III-15, III-
18, III-26, IV-11, IV-13, IV-16, IV-17, IV-18 and IV-21) agreed
to participate in biochemical testing, image examinations and RET
screening (Tables 1 and 2). All had normal Ct, CEA and US
images except III-15, III-23, IV-21 and III-12 with p.C634Y.
Then a total thyroidectomy with modified bilateral (III-15 and III-
23) or bilateral level VI lymph node dissection (IV-21) and a total
bilateral laparoscopic adrenalectomy with CO2 pneumoperitone-
um (III-12) were performed. Histopathological examination
revealed bilateral PHEO in III-12 and bilateral multi-focal
MTC with lymph node metastases in III-15, III-20 and III-23,
while IV-21 showed no evidence of lymph node metastases. All six
patients (III-12, III-15, III-20, III-23, IV-10 and IV-21) were
followed up. Biochemical and imaging examination did not reveal
any evidence of recurrence of MTC or PHEO, and showed no
HPT during this period except for III-12. Biochemical examina-
tion of III-12 showed Ct was 1360 ng/L and CEA was 13.2 ng/
Table 1. Clinical presentations of patients with MTC and RET mutations.
Individual Sex Age Mutation and origin Pre-op Ct US results Histology ADM (years) LN+/resected
a pTNM
IV-10 F 22 p.C634Y/V292M/R67H/R982C,
Pat and Mat
343.92 Negative; TT Bi-MTC 13 (onset) 5/51 T2N1aM0
(stage III)
II-5 M 70 p.V292M/R67H/R982C, Pat 76.35 Negative; TT Bi-MTC 70 0/15 T1N0M0
(stage I)
III-3 M 48 p.V292M/R67H/R982C, Pat 49.86 Negative; AS No spec 48 No spec No spec
III-8 F 46 p.V292M/R67H/R982C, Pat 43.72 Negative; AS No spec 46 No spec No spec
III-11 M 44 p.V292M/R67H/R982C, Pat 58.66 Negative; TT Bi-CCH 44 - -
IV-3 M 22 p.V292M/R67H/R982C, Pat 39.34 Normal - - - -
IV-7 F 19 p.V292M/R67H/R982C, Pat 59.21 Normal - - - -
III-12* F 43 p.C634Y, Mat 408.32 Negative; TT Bi-MTC 28 (onset) 3/40 T2N1aM0
(stage III)
III-15 M 41 p.C634Y, Mat 104.35 Negative; TT Bi-MTC 39 2/22 T1N1aM0
(stage III)
III-20 F 56 p.C634Y, Mat 260.49 Negative; TT Bi-MTC 52 (onset) 3/23 T1N1aM0
(stage III)
III-23 M 50 p.C634Y, Mat 163.23 Negative; TT Bi-MTC 50 (onset) 2/26 T2N1aM0
(stage III)
IV-21 M 25 p.C634Y, Mat 34.70 Negative; TT Bi-MTC 24 0/15 T1N0M0
(stage I)
*proband; F, female; M, male; Pat, paternal family; Mat, maternal family; Pre-op Ct, pre-operative calcitonin (ng/L); US, ultrasound; AS, awaiting surgery; ADM, age at
diagnosis of MTC; pTNM, tumour stage; TT, total thyroidectomy; Bi-, Bilateral; No spec, no specimen.
aLN+ includes positive lymph nodes proven on histopathology; resected includes lymph node resected.
doi:10.1371/journal.pone.0020353.t001
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of MTC with lymph node metastases.
The proband’s husband (III-11) and his family members have not
felt any special abnormality to date. As p.V292M/R67H/R982C and
p.C634Y/V292M/R67H/R982C mutations of RET were found by
WES in him and his daughter (IV-10) respectively in 2010, neck US
screening was performed on all 6 carriers and the results disclosed
multi-focal hypoechoic nodules (range 0.4–0.8 cm) in the upper third
of left/right or both thyroid lobes in II-5, III-3, III-8 and III-11 but not
in IV-3 and IV-7. Ct was normal while the pentagastrin-stimulated Ct
was slightly elevated in II-5 and III-11. In 2010, a total thyroidectomy
with modified bilateral level VI lymph node dissection was performed
in II-5, then histopathological examination revealed bilateral MTC
without lymph node metastases (T1N0M0, Table 1). III-11 underwent
a prophylactic total thyroidectomy in 2010 at the age of 44, and
histopathology revealed bilateral multi-focal C-cell hyperplasia (CCH)
without evidence of MTC. III-3 and III-8 await thyroidectomy, while
IV-3 and IV-7 are being followed up (Table 1). None of the 6 carriers
showed abnormalities in the parathyroid or adrenal glands.
We excluded the possibility of HSCR in this family based on the fact
that none of the affected individuals presented evidence of HCSR
involving severe constipation, vomiting, abdominal distension, or
enterocolitis. Meanwhile, cutaneous lichen amyloidosis was also
excluded because there was no evidence of pruritic lichenoid skin
lesion located on the upper back.
Exome Sequencing Identified Four RET Missense Variants
We generated an average of approximately 4.0 billion bases of
sequence per affected individual as paired-end, 88-bp reads, and
the fraction of effective bases on target was about 64% with a






Catecholamine serum level (ng/L)
(Normal: DA,100; E,600; NE,100) Tumor size AT Histology
III-12 F 43 p.C634Y, Mat Normal L: 2.562.062.0 cm; R: 1.561.261.0 cm Yes Bi-PHEO
III-23 M 45 p.C634Y, Mat Elevated (DA: 278.13; E: 925;
NE: 6670.7)
L: 4.363.662.8 cm; 1.260.860.8 cm; R:
4.562.261.6 cm
Yes Bi-PHEO
F, female; M, male; Mat, maternal family; DA, dopamine; E, epinephrine; NE, norepinephrine; L, left; R, right; AT, adrenalectomy; Bi-, Bilateral.
doi:10.1371/journal.pone.0020353.t002
Table 3. Overview of whole exome sequencing data production.
Sample II-5 III-10 III-11 III-12 IV-10 IV-11
Initial bases on target: 37,640,396 37,563,132 37,640,396 37,563,132 37,563,132 37,640,396
Initial bases near target: 57,236,802 57,118,957 57,236,802 57,118,957 57,118,957 57,236,802
Initial bases on or near target: 94,877,198 94,682,089 94,877,198 94,682,089 94,682,089 94,877,198
Total effective reads: 41,670,096 42,750,582 41,649,379 40,395,197 48,247,010 42,912,533
Total effective yield (Mb): 3,660.53 3,756.66 3,645.29 3,567.62 4,238.35 3,771.98
Average read length (bp): 87.85 87.87 87.52 88.32 87.85 87.90
Effective sequence on target (Mb): 2,350.98 2,380.88 2,328.08 2,277.75 2,779.49 2,405.11
Effective sequence near target (Mb): 531.72 572.00 495.98 530.61 599.20 544.23
Effective sequence on or near target (Mb): 2,882.70 2,952.88 2,824.06 2,808.36 3,378.69 2,949.34
Fraction of effective bases on target: 64.20% 63.40% 63.90% 63.80% 65.60% 63.80%
Fraction of effective bases on or near target: 78.80% 78.60% 77.50% 78.70% 79.70% 78.20%
Average sequencing depth on target: 62.46 63.38 61.85 60.64 74.00 63.90
Average sequencing depth near target: 9.29 10.01 8.67 9.29 10.49 9.51
Mismatch rate in target region: 0.57% 0.57% 0.56% 0.56% 0.59% 0.56%
Mismatch rate in all effective sequence: 0.59% 0.59% 0.58% 0.57% 0.61% 0.58%
Base covered on target: 37,265,593 37,219,081 37,283,514 37,159,448 37,260,142 37,287,524
Coverage of target region: 99.00% 99.10% 99.10% 98.90% 99.20% 99.10%
Base covered near target: 45,466,110 46,437,695 44,284,058 45,892,786 45,603,313 46,116,042
Coverage of flanking region: 79.40% 81.30% 77.40% 80.30% 79.80% 80.60%
Fraction of target covered with at least 206 80.60% 81.70% 80.30% 80.20% 84.50% 81.40%
Fraction of target covered with at least 106 91.30% 91.90% 91.20% 91.00% 93.10% 91.70%
Fraction of target covered with at least 46 96.70% 96.90% 96.70% 96.50% 97.30% 96.90%
Fraction of flanking region covered with at least 206 14.00% 15.30% 12.90% 13.90% 16.00% 14.40%
Fraction of flanking region covered with at least 106 27.90% 29.90% 26.00% 28.10% 29.90% 28.60%
Fraction of flanking region covered with at least 46 49.70% 52.20% 47.10% 50.40% 51.20% 50.90%
doi:10.1371/journal.pone.0020353.t003
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depth of coverage, more than 99% of the targeted bases were
sufficiently covered to pass our thresholds for variant calling
(Table 3). We focused on nonsynonymous (NS) variants, splice
acceptor, and donor site mutations (SS), anticipating that
synonymous variants would be far less likely to be pathogenic.
Filtering against public SNP databases, the 1000 Genome
Project, eight HapMap exomes, the in-house exome database
BGI provided and two normal individuals from the family, 30
genes harboring 95 different NS/SS were shared by the four
patients. We just focused on the RET gene and found four
recurrent missense substitutions: c.G200A (p.R67H), c.G874A
(p.V292M), c.G1901A (p.C634Y) and c.C2944T (p.R982C)
(Sequence Read Archive accession number: SRA029363.2).
Analysis to explain or eliminate the pathogenicity of the other
29 genes (including 90 NS/SS) in MEN2A is ongoing and further
data will be reported elsewhere.
Validation of the RET Germline Mutation
The Sanger sequencing scan of the whole RET gene was
completely consistent with the whole exome sequencing. The
proband (III-12) carried the p.C634Y mutation within exon 11,
and so did her family members III-15, III-20, III-23 and IV-21.
Unfortunately and interestingly, the proband’s husband (III-11)
and his family members II-5, III-3, III-8, IV-3 and IV-7 carried
the p.R67H mutation within exon 2, the p.V292M mutation
Figure 2. Portion of DNA sequences and polyacrylamide gel electrophoresis analysis of restriction endonuclease digestion. A,
Maternal origin MEN 2A (III-23, III-12 and IV-10) were heterozygous for c.G2901A (p.C634Y), whereas paternal origin members (III-11, III-6, II-5, II-6 and
III-3) were homozygous for the wild-type allele. This mutation was confirmed by Kpn I digestion. B, IV-10 and paternal origin FMTC (III-11, II-5, and III-3)
demonstrated a heterozygous c.G874A (p.V292M) mutation which created the restriction enzyme site for Nco I, whereas maternal origin members (III-
12 and IV-11), and two unaffected paternal members (III-10 and IV-8) showed the normal sequence. C, A heterozygous c.C2944T (p.R982C)
polymorphism from IV-10 and paternal origin FMTC (III-11, II-5 and III-3) was found, whereas the maternal origin members III-12 and IV-11 and two
unaffected paternal members (III-10 and IV-8) were homozygous for the wild-type allele. This polymorphism was validated by Rsa I digestion.
doi:10.1371/journal.pone.0020353.g002
Whole Exome Sequencing in MEN 2A/FMTC
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20353within exon 5 and the p.R982C polymorphism within exon 18
(Table 1). Thus, their daughter (IV-10) inherited four substitutions
of p.C634Y/V292M/R67H/R982C (GenBank accession number
for p.C634Y: JF276429; p.V292M/R67H/R982C: JF273638), of
which p.C634Y, p.V292M and p.R982C were respectively
confirmed by Kpn I, Nco I and Rsa I digestion (Fig. 2). Genomic
DNA and RT-PCR product sequencing from tumor tissues were
both consistent with the results from blood and presented
heterozygosity (Fig. 3). The four alterations were absent in 100
healthy controls. Haplotype analysis of four microsatellite markers
from the 9 related members (II-5, II-6, III-10, III-11, III-12, III-
13, III-15, IV-10 and IV-11) confirmed that p.C634Y was of
maternal origin and p.V292M/R67H/R982C was paternal and
located in a common allele (Fig. 4).
Discussion
We used WES here and successfully confirmed several
pathogenic variants in a Chinese family with MEN 2A/FMTC.
WES can serve as a genome-wide scan for the causative gene [20].
Moving along the spectrum from rare monogenic disorders to
complex common diseases, it is likely that the increasing extent of
genetic heterogeneity will need to be matched by increasingly large
sample sizes [23]. Meanwhile, although this approach could be
underemployed for mutation analysis of known genes, especially
those with hot-spot mutations, our case serves as a proper example
of genetic diagnosis of a pathogenic gene that harbors a large
myriad of exons, particularly those without hot-spot mutational
sites, such as Cornelia de Lange syndrome with causative gene
NIPBL embracing 47 exons without hot-spot mutational sites [24].
WES can reduce the missed detection of some rare mutations in
cases with hot-spot mutations and serve as a more direct method
than cumbersome Sanger sequencing of a myriad of PCR
fragments [19]. Moreover, WES could be a better choice for
some diseases with overlapping symptoms that might be
ambiguously associated with many pathogenic genes, in which
event the detection of mutation by Sanger sequencing could be
time-consuming and labor-intensive [18,19]. The standard
sequencing of a single PCR fragment in molecular diagnosis costs
600 Yuan (,$91) for Zhejiang University-Adinovo Center for
Genetic and Genomic Medicine. This price includes consumables,
equipment amortization, personnel salary and corporate profit.
Therefore, the total cost of sequencing the entire RET coding
sequence, which requires 21 PCR fragments, is 12600 Yuan
(,$1909). In comparison, the all-inclusive cost of WES per sample
is 25000 Yuan (,$3788), about twice as much as Sanger
sequencing. However, WES would be a more cost-effective and
robust method for a causative gene embracing more than 42 exons
(25200 Yuan, ,$3819) such as NIPBL. Additionally, with rapid
commercialization, the cost of WES for gene testing will be
considerably reduced in the coming years [19].
The most frequent RET mutations responsible for MEN 2A are
p.C634Y/R/W/F/S/G/L, which target to one of five cysteine
residues in the extracellular domain of RET [5,25]. It seems that
different amino acid substitutions within codon 634 present
different prevalence in different populations but cause indistin-
guishable phenotypes, although one study suggested that individ-
uals with p.C634R have significantly more distant metastases at
diagnosis than those with p.C634Y/W [25,26]. In this study, the
clinical features seemed similar to those reported by Zhou et al
Figure 3. Portion of genomic DNA and RT-PCR product sequencing from tumor tissues. A, Direct sequencing consequences of RT-PCR
products from PHEO tissue of III-12 indicated a heterozygous G/A mutation at codon 634, which was consistent with the results of DNA from blood
and tumor tissues and whole exome sequencing. B, C, D, Direct sequencing consequences of RT-PCR products from MTC tissue of III-11 indicated
heterozygous G/A, C/T, and G/A mutations at codons 292, 982, and 67, respectively, which was consistent with the results of DNA from blood and
tumor tissues and whole exome sequencing.
doi:10.1371/journal.pone.0020353.g003
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Chinese.
Previous studies provided evidence that some variants play
roles in modifying other variants in the genesis of MEN 2A or
FMTC. The p.V292M mutation maps to the third cadherin-like
domain of RET and is a gain-of-function alteration with weaker
pathogenicity [12]. An Italian MEN 2A patient with p.V292M
presented at the age of 44 with classic PHEO and a 4-mm
unifocal MTC in the right thyroid lobe [12]. Dvorakova et al
reported another mutation, p.G321R, within exon 5 in a three-
generation Czech kindred with FMTC [27]. Among 4 affected
paternal members, one (aged 70) had MTC, one (aged 42) had
CCH, and two (aged 27 and 52) had no evidence of either [27].
This indicated that mutations in the extracellular cadherin-like
domain cause a comparatively mild clinical phenotype. Clinical
investigation in our patients revealed that only one (II-5) had
bilateral MTC at the age of 70, one (III-10) had bilateral CCH at
age 44, and two (III-8 and III-3) had bilateral multiple nodules in
both thyroid lobes at ages 46 and 48, which may be caused by the
RET p.V292M/R67H/R982C mutation. In contrast to the
previous literature, our patients presented with a later onset of
MTC or CCH and showed no evidence of PHEO even in the 70-
year-old male (II-5), while the previously reported case with
p.V292M had PHEO before MTC [12]. The p.V292M/R67H/
R982C compound mutation may predispose to the FMTC
phenotype. Previously-reported RET double mutations associated
Figure 4. Haplotype analysis. Four microsatellite markers (D10S197, D10S196, D10S1652 and D10S537) from 9 related members (II-5, II-6, III-10, III-
11, III-12, III-13, III-15, IV-10 and IV-11) demonstrated that the p.C634Y/V292M/R67H/R982C mutation did not arise on a common chromosome;
p.C634Y was of maternal origin and p.V292M/R67H/R982C was paternal and located in a common allele.
doi:10.1371/journal.pone.0020353.g004
Table 4. Summary of reported RET double mutations associated with MEN 2.
Time Mutation and pattern Phenotype Origin Reference
1999 p.C634R/A640G, cis Calcitonin-producing PHEO Italy [43]
2000 p.V804M/Y806C, cis MEN 2B Japan [33,34]
2000 p.V804M/R844L, cis FMTC with a mild phenotype Germany [36]
2001 p.V804M/V778I, cis FMTC with corneal nerve thickening Spain [35]
2002 p.V804M/S904Y, cis Atypical MEN 2B Netherlands [42]
2002 p.C634R/V648I, trans Adrenocorticotropic hormone-producing PHEO Brazil [38]
2005 p.C634S/A641S, cis MTC (10/10), PHEO (2/10), HPT (0/10) Slovakia [41]
2006 p.V804M/E805K, cis Classical features of MEN 2B United Kingdom [31]
2010 p.C634Y/Y791F, cis High penetrance of PHEO Brazil [13]
doi:10.1371/journal.pone.0020353.t004
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2A seems to be impaired by certain RET polymorphisms [28–30],
while polymorphisms involving genes whose products interact
with RET or components of the RET signaling pathway have also
been reported to modify the risk of MTC [31,32]. Iwashita et al
demonstrated that the transforming activity of RET with the cis
p.V804M/Y806C mutation is dramatically higher than that of
RET with a single p.V804M or p.Y806C mutation [33,34].
Kasprzak et al indicated that p.V778I might potentially affect the
phenotype through an additive effect in the presence of p.V804M
in a Spanish family [35]. Recent studies showed that p.Y791F is
definitely not a pathogenic mutation for MEN 2, but the
p.C634Y/Y791F cis double mutation carries a codon 634-like
pattern of MTC development and is associated with increased
susceptibility to unusually large bilateral PHEO [13,32].
Meanwhile, Bartsch et al concluded that the RET p.V804M/
R844L cis double mutation predisposes the individual to the
development of FMTC with a mild phenotype [36]. In these
events, it seems that p.Y806C, p.V778I and polymorphism
p.Y791F have additive effects to p.V804M and p.C634Y,
respectively, while p.R844L has an inhibitory modifying effect
on p.V804M. In the present study, entire RET screening showed
that cis p.R67H/R982C combined with p.V292M in cis co-
segregated with the FMTC phenotype. Since we did not find
PHEO, in contrast to the phenotype of p.V292M reported
previously, we speculated that the cis p.R67H/R982C variant has
a modifying effect on the disease and may inhibit the genesis of
PHEO, although p.R982C seems to have normal biological and
biochemical behavior in in vitro expression experiments [14,37],
and p.R67H/R982C was reported to be associated with
congenital central hypoventilation syndrome [15].
Previous studies have shown that double RET mutations may be
associated with unusual MEN 2 phenotypes (Table 4). The case
with p.C634Y/V292M/R67H/R982C (IV-10) had a more
advanced and large bilateral MTC with lymph node metastases
(Table 1), in contrast to p.C634Y (including contemporary IV-21)
or p.V292M/R67H/R982C (including contemporaries IV-3 and
IV-7) carriers, but lacked PHEO and HPT. Nunes et al believed
that the RET trans p.C634R/V648I double mutation may have
modified and contributed to the rare MEN 2A phenotype in a
patient with bilateral adrenocorticotropin-producing PHEO and
MTC [38]. A previous study showed that the potential
physiochemical effects of p.V804M and p.E805K substitutions in
silico are moderately deleterious in isolation but severely deleteri-
ous in cis combination due to their distinctly synergistic effect [39].
These two cases provided the evidence that these two pathogenic
mutations together amount to a more deleterious double mutation
than that in isolation, which might explain the higher MTC
pathogenicity of p.C634Y/V292M/R67H/R982C due to the
additive effect of p.V292M/R67H/R982C and p.C634Y in trans.
A ‘‘second hit’’ mechanism advocates that allelic imbalance
between mutant and wild-type RET is a possible mechanism of
tumorigenesis in some patients with MEN 2A-related MTC [40].
Our data illustrated that the consistency of sequencing of genomic
DNA from blood and tumor tissues and the cDNA from tumor
tissues refuted the loss of heterozygosity and are inconsistent with
the ‘‘second hit’’ mechanism [40]. However, the wild-type RET
might play a neutralizing role and thereby partly compensate for
the activating effects of the mutant allele, but this protective effect
of wild-type RET may disappear in the trans double mutant, which,
from another perspective, could explain the more aggressive
pathogenicity of the p.C634Y/V292M/R67H/R982C compound
mutation [40]. Due to the young age of 22 years in IV-10, the
combination of p.C634Y and p.V292M/R67H/R982C, and the
reduced penetrance of PHEO and HPT, it is too early to ascertain
whether she will develop PHEO and HPT.
Briefly, WES provides an instructive, comprehensive, fast and
accurate method for genetic diagnosis of a disease whose
pathogenic genes embrace a large cohort of exons. Our case
suggests the importance of extending RET sequencing studies to
the gene’s entire coding region, even though initial testing of a
patient with clinical signs of MEN-2 reveals RET hot-spot
mutations, or when genotype-phenotype discrepancies emerge.
Meanwhile, in the present study, the p.R67H/R982C polymor-
phism had a modifying effect on the disease and may inhibit the
genesis of PHEO, and p.C634Y/V292M/R67H/R982C may
lead to higher MTC pathogenicity due to the additive effect of
p.V292M/R67H/R982C and p.C634Y in trans combination.
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